دورية أكاديمية
أعرض في EDS

The prognosis of NX stage in patients with pT1 papillary thyroid cancer who underwent lobectomy.

التفاصيل البيبلوغرافية
العنوان: The prognosis of NX stage in patients with pT1 papillary thyroid cancer who underwent lobectomy.
المؤلفون: Ahn HR; Department of Surgery, Research Institute of Clinical Medicine, Jeonbuk National University Hospital, Jeonbuk National University and Biomedical Research Institute, Jeonju, Korea., Kang SY, Youn HJ, Jung SH
المصدر: Medicine [Medicine (Baltimore)] 2023 May 12; Vol. 102 (19), pp. e33632.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 2985248R Publication Model: Print Cited Medium: Internet ISSN: 1536-5964 (Electronic) Linking ISSN: 00257974 NLM ISO Abbreviation: Medicine (Baltimore) Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Hagerstown, Md : Lippincott Williams & Wilkins
مواضيع طبية MeSH: Carcinoma, Papillary*/pathology , Thyroid Neoplasms*/pathology , Adenocarcinoma*/surgery, Humans ; Adult ; Middle Aged ; Thyroid Cancer, Papillary/surgery ; Retrospective Studies ; Prognosis ; Lymphatic Metastasis ; Thyroidectomy ; Neoplasm Recurrence, Local/pathology
مستخلص: Lymph node (LN) metastasis is known to impact the prognosis of patients with well-differentiated thyroid cancer. Herein, we aimed to determine the effect of NX stage on the prognosis of patients with papillary thyroid cancer who underwent thyroid lobectomy. We initially selected 1257 patients who underwent thyroid cancer surgery from 2012 to 2015. Of the 1257 patients, we included 556 in the analysis, excluding patients diagnosed with other types of thyroid cancer, those who underwent total or completion thyroidectomy, and those diagnosed with LN metastasis prior to surgery. The median follow-up time was 61.8 months (range: 12.3-108.9 months). After dividing the patients into N0, N1, and NX stage groups, we performed univariate and multivariate analyses. The 5-year recurrence-free survival (RFS) was analyzed using R version 3.2.5. The mean patient age was 45.0 ± 10.9 years. Of the 556 patients, 336 patients (60.4%) were diagnosed with N0 stage, 134 (24.1%) were N1 stage, and 86 (15.5%) were NX stage. Univariate and multivariate analyses were performed to identify prognostic factors for RFS. Considering gender, age, tumor size, surgery types, extrathyroidal extension, multifocality, and recurrence, no statistically significant differences were noted between the 3 groups. The 5-year RFS rates were 98.8%, 95.5%, and 97.6% for N0, N1, and NX groups, respectively, without significant differences between the 3 groups (P = .56). Considering the T1b stage, the 5-year RFS rates were 100%, 93.1%, and 93.7% in the N0, N1, and NX groups, respectively, with a statistically significant difference between the 3 groups (P = .018). Accordingly, the NX status cannot be deemed a prognostic factor for RFS in patients with papillary thyroid cancer who underwent thyroid lobectomy. However, the benefit of prophylactic central-LN dissection should be considered in patients with well-differentiated thyroid cancer diagnosed with T1b stage.
Competing Interests: The authors have no conflicts of interest to disclose.
(Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.)
References: J Clin Endocrinol Metab. 2004 Aug;89(8):3713-20. (PMID: 15292295)
World J Oncol. 2022 Jun;13(3):136-144. (PMID: 35837319)
J Surg Oncol. 2009 Mar 15;99(4):186-8. (PMID: 19170045)
Clin Endocrinol (Oxf). 2018 Jul;89(1):100-109. (PMID: 29672893)
Clin Exp Otorhinolaryngol. 2020 May;13(2):194-202. (PMID: 32434311)
Ann Surg. 2003 Mar;237(3):399-407. (PMID: 12616125)
Lancet Diabetes Endocrinol. 2021 Apr;9(4):225-234. (PMID: 33662333)
Surgery. 2008 Dec;144(6):980-7; discussion 987-8. (PMID: 19041007)
Front Endocrinol (Lausanne). 2020 Feb 27;11:90. (PMID: 32174889)
Arch Otolaryngol Head Neck Surg. 2006 Jun;132(6):650-4. (PMID: 16785411)
Surgery. 2009 Oct;146(4):696-703; discussion 703-5. (PMID: 19789029)
Eur Arch Otorhinolaryngol. 2020 Mar;277(3):873-879. (PMID: 31792652)
Head Neck. 2013 Nov;35(11):1616-20. (PMID: 23322499)
Am J Transl Res. 2018 Nov 15;10(11):3782-3789. (PMID: 30662628)
Ann Surg Oncol. 2008 Feb;15(2):397-9. (PMID: 18058179)
Thyroid. 2016 Jan;26(1):1-133. (PMID: 26462967)
J Am Coll Surg. 2016 May;222(5):853-64. (PMID: 27113516)
Thyroid. 2017 Jun;27(6):751-756. (PMID: 28463585)
تواريخ الأحداث: Date Created: 20230512 Date Completed: 20230515 Latest Revision: 20230515
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC10174359
DOI: 10.1097/MD.0000000000033632
PMID: 37171355
قاعدة البيانات: MEDLINE
الوصف
تدمد:1536-5964
DOI:10.1097/MD.0000000000033632